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ABSTRACT
Colorectal cancer (CRC) is one of the most dangerous types of malignant tumors, 
and cancer metastasis is a major factor in the failure of CRC therapy. Recently, 
LOXL2 (lysyl oxidase-like 2) has been shown to represent a regulator of epithelial-
mesenchymal transition (EMT) in different cancer types. However, LOXL2 has not been 
reported to be involved in CRC metastasis. In this study, we demonstrated that LOXL2 
expression is strongly correlated with the rate of CRC metastasis, it participates in the 
regulation of EMT-related molecule expression in CRC cells in vitro, and it is involved 
in migratory potential alterations. Additionally, tissue microarray analysis of CRC 
patients showed an increase in the probability of developing CRC distant metastasis 
and a decrease in the survival rate of patients with high LOXL2 expression. The 
results obtained in this study indicate that LOXL2 is involved in the development and 
progression of CRC metastasis, and therefore, its expression levels may represent a 
useful prognostic marker.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer worldwide (~10% of all cancer cases) and the 
second most prevalent cancer (2.4 million people) [1, 2]. 
Approximately 700,000 people yearly die of CRC, 
and the development of metastatic disease is the most 
frequent cause of death [1, 3, 4]. The majority of CRC 
patients is diagnosed at the advanced cancer stage, and 
the risk of metastatic progression is increased in these 
patients [5]. Therefore, further studies should focus on 
the molecular mechanisms underlying the development of 
CRC metastasis, which may lead to the development of 
improved treatment strategies. 
Epithelial-mesenchymal transition (EMT) is 
a molecular process essential for cancer metastasis 
initiation. During the process of EMT, cell properties 
are altered, and those required for migration, invasion 
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into the extracellular matrix (ECM), and extravasation/
intravasation, are acquired [6, 7]. In addition to these 
changes, the changes in the levels of many molecules can 
be observed, including several regulatory molecules that 
modulate the EMT.
Lysyl oxidase-like 2 (LOXL2) is a member of 
lysyl oxidase (LOX) family, which includes molecules 
sharing a highly conserved catalytic domain at the 
C-terminus [8]. In physiological conditions, LOXL2 is 
involved in the extracellular matrix (ECM) remodeling. 
Similar to the other members of LOX family, LOXL2 
induces the crosslinking of ECM collagen and elastin 
by the deamination of peptidyl lysine residues [8, 9]. 
Recently, several groups reported that LOXL2 may 
represent a modulator of EMT, through the regulation 
of EMT-inducing transcription factors, focal adhesion 
kinase (FAK)/Src signaling pathway, and the epigenetic 
regulation of EMT-related genes [10–12].
Furthermore, many studies, including ours, 
investigated and showed the clinical relevance of 
LOXL2 expression during the metastasis of breast [13], 
gastric [14], liver [15], esophageal [16], and pancreatic 
[17] cancers. However, LOXL2 in CRC has been rarely 
investigated [18, 19], and these studies focused on LOXL2 
expression in association with CRC survival rate and 
tumor differentiation, and, to the best of our knowledge, 
the correlation between LOXL2 expression and the 
development of CRC metastasis has not been previously 
investigated. However, since the loss of the heterozygosity 
(LOH) locus is frequently found in patients with colon 
cancer metastasis, and LOXL2 was reported to be one of 
the genes located at this locus [20], this may indicate a 
correlation between the expression levels of this molecule 
and the development of CRC metastasis. Therefore, we 
investigated the role of LOXL2 in the development and 
progression of CRC metastasis both in vitro and in patients.
RESULTS
CRC cell migratory potential is associated with 
LOXL2 expression
We first examined LOXL2 expression levels in 
several CRC cell lines. LOXL2 was shown to be expressed 
in SW480 cells, but rarely detected in other investigated 
cell lines, at mRNA and protein levels (Figure 1A and 1B). 
Although the expression of LOXL2 was determined to 
be lower than that determined in MDA-MB-231 cells, 
LOXL2-positive breast cancer cells [13], SW480 cells 
showed considerably higher migratory potential than 
LOXL2-negative cells, in migration assay and wound 
healing assay (Figure 1C and Supplementary Figure 1A). 
Cell migration rate was shown to be independent of the 
growth rate of different cells (Supplementary Figure 1B).
Next, we examined the migratory phenotype by 
using LOXL2 knockdown and ectopic expression in 
Figure 1: Correlation between LOXL2 expression levels and migratory potential of different CRC cells in vitro. 
(A) LOXL2 expression in five CRC cell lines. Distilled water was used as a negative control (N.C.). (B) LOXL2 protein levels in CRC 
cells. MDA-MB-231 was used as a positive control (P.C.). (C) Motility of different CRC cells in vitro, determined in wound healing assay. 
Representative figures obtained in three independent experiment are shown.
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SW480 and SW620 (LOXL2-negative) cells, respectively. 
We demonstrated that LOXL2 knockdown led to a 
significant reduction in the migratory potential of SW480 
cells (Figure 2A and Supplementary Figure 2), while its 
ectopic expression led to the stimulation of SW620 cell 
migratory potential (Figure 2B). 
Furthermore, we examined the ability of these cells 
to cross the endothelial cell barrier, represented by human 
umbilical vein endothelial cells (HUVEC), which mimics 
intra/extravasation process during metastasis. We observed 
that many SW480 cells were able to penetrate HUVEC cell 
layer, but LOXL2 silencing led to a decrease in this potential 
(Figure 3A). SW620 cells transfected with the LOXL2 
expression plasmid showed an increase in the HUVEC layer 
penetration, compared with that of the cells transfected with 
a mock plasmid (Figure 3B). Additionally, we confirmed 
that LOXL2 knockdown and overexpression did not affect 
cellular growth rates (Supplementary Figure 3).
LOXL2 regulates the expression of EMT-related 
molecules in CRC cells
In order to investigate the molecular mechanism 
underlying LOXL2-dependent alterations in migratory 
potential, we examined LOXL2 knockdown/ectopic 
expression-induced alterations in SW480 and SW620 
cells, respectively (Figure 4A). We showed that LOXL2 
knockdown leads to a decrease in the expression 
of vimentin, a mesenchymal marker, while LOXL2 
overexpression upregulated the expression of this protein. 
Conversely, we obtained opposite effects on the expression 
of the epithelial marker, E-cadherin. Similar results were 
obtained at mRNA level (Figure 4B).
Furthermore, since the activation of FAK/Src 
pathway is known to promote EMT, several reports 
indicated that the changes in ECM stiffness can lead 
to the activation of FAK/Src signaling [21–23], and 
LOXL2 is known to be involved in the ECM remodeling, 
we investigated whether LOXL2 is involved in the 
activation of FAK/Src by determining the levels of 
phosphorylated FAK/Src (Figure 4C). LOXL2 knockdown 
and overexpression were shown to down- and upregulate, 
respectively, FAK/Src phosphorylation. Snail protein, one 
of the major transcription factors involved in the EMT 
process, was shown to be regulated by LOXL2, and LOXL2 
knockdown led to a decrease, while its overexpression led 
to an increase in Snail levels (Figure 4C). 
Correlation between LOXL2 expression levels 
and clinicopathological characteristics of CRC 
patients
We investigated the correlation between LOXL2 
expression levels and CRC metastasis rate in patients, 
by immunohistochemically (IHC) examining LOXL2 
expression in cancer tissue samples obtained from CRC 
patients. LOXL2 expression was classified as low or 
high (Figure 5A), and, of 223 patients examined in our 
Figure 2: Migratory potential alterations induced by the changes in LOXL2 expression. (A) Transwell migration of LOXL2-
knockdown SW480 cells. Images were obtained 36 h after seeding. (B) Transwell migration of LOXL2-overexpressing SW620 cells. 
Images were obtained 72 h after seeding. Results were obtained from three independent experiments, and bar graphs in (A) and (B) 
represent cell number per image field (mean ± standard deviation).
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study, the samples obtained from 28 patients (12.1%) 
were shown to have high LOXL2 expression levels, 
which was shown to be significantly associated with 
the presence of distant metastasis (p = 0.046). Increased 
LOXL2 expression levels tended to be associated 
with the survival of the patients (p = 0.066). Other 
clinicopathological parameters, including patient age, 
sex, histological grade, pathologic T stage, overall cancer 
stage, and the presence of lymph node metastasis were 
not associated with LOXL2 expression (p > 0.05 for all). 
Clinicopathological characteristics in patients categorized 
by LOXL2 expression levels are summarized in Table 1. 
Patients with high LOXL2 expression levels were shown 
to have a shorter overall survival (p = 0.024; Figure 5B) 
than those with low LOXL2 expression.
DISCUSSION
Here, we investigated the role of LOXL2 in the 
EMT progression in CRC, and clinical consequences 
of the changes in LOXL2 expression. We observed that 
LOXL2-positive CRC cells have an increased migratory 
potential, in comparison with that of the LOXL2-negative 
cells; LOXL2 knockdown/ectopic expression was shown 
to affect this migratory potential in these cells in vitro, 
demonstrating that LOXL2 promotes the EMT process, 
while the results obtained by analyzing clinicopathological 
parameters strongly support the pro-metastatic role of 
LOXL2 in CRC progression.
Various molecular mechanisms underlying LOXL2-
dependent EMT induction have been reported. Peinado 
et al. [10] demonstrated that LOXL2 stabilizes Snail, one 
of the major transcription factors inducing EMT process, 
by oxidizing lysine 98 and 137 residues, and this process 
and the phosphorylation of Snail by glycogen synthase 
kinase 3 beta (GSK3β), which is a signal for proteasome-
dependent degradation, are considered antagonistic 
processes. Here, we demonstrated that the changes in 
LOXL2 expression affect Snail at protein, but not at 
mRNA level, suggesting that LOXL2 modulates SNAI1 
at the post-translation levels, which further affects the 
migratory potential of CRC cells in vitro.
Other members of LOX family have been suggested 
to induce the activation of EMT, including LOX, which 
was reported to be involved in the development of CRC 
metastasis [24], through the activation of FAK/Src 
signaling pathway, which induces the EMT process, and 
the activation of the pathway induced by ECM remodeling, 
which may trigger the activation of cellular receptors, 
such as integrin. Previously, several studies reported that 
LOXL2 induces EMT in breast, gastric, and pancreatic 
cancer cells, which is accompanied by the activation of 
Figure 3: Effects of LOXL2 silencing/ectopic expression on the migration of CRC cells through the endothelial barrier. 
(A) SW480 cells transfected with siControl/siLOXL2 oligonucleotide were seeded on HUVECs, and images were obtained 36 h after 
seeding. (B) SW620 cells transfected with mock/LOXL2-expressing plasmids were seeded on HUVECs, and images were obtained 72 h 
after seeding. Results were obtained from three independent experiments and bar graphs in (A) and (B) represent cell number per image 
field (mean ± standard deviation).
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FAK/Src pathway [13, 14, 17]. This may suggest that 
all members of LOX family induce EMT through ECM 
remodeling. However, LOXL2 may play the key role in 
this process, because this is the only member of LOX 
family that can stabilize Snail [10]. Here, we observed that 
LOXL2 induces FAK/Src activation and regulates Snail 
in vitro, and therefore, we suggest that LOXL2 may have 
dual effects on the EMT activation in CRC cells. 
Table 1: Clinicopathological characteristics of CRC patients categorized based on their LOXL2 
expression levels
Category Variables
No. of cases High expression (%) Low expression (%)
p-value
(n = 223) (n = 28) (n = 195)
Age < 60 97 12 (42.9) 85 (43.6) 0.942
≥ 60 126 16 (57.1) 110 (56.4)
Gender Female 81 13 (46.4) 68 (34.9) 0.235
Male 142 15 (53.6) 127 (65.1)
Location Colon 112 13 (46.4) 99 (50.8) 0.668
Rectum 111 15 (53.6) 96 (49.2)
Histologic grade WD to MD 205 25 (89.3) 180 (92.3) 0.584
PD 18 3 (10.7) 15 (7.7)
Pathologic T stage T1 and T2 30 3 (10.7) 27 (13.8) 0.650
T3 and T4 193 25 (89.3) 168 (86.2)
LNM Absent 103 11 (39.3) 92 (47.2) 0.434
Present 120 17 (60.7) 103 (52.8)
Distant metastasis Absent 188 20 (71.4) 168 (86.2) 0.046
Present 35 8 (28.6) 27 (13.8)
Overall cancer stage I 23 1 (3.6) 22 (11.3) 0.104
II 73 9 (32.1) 64 (32.8)
III 92 10 (35.7) 82 (42.1)
IV 35 8 (28.6) 27 (13.8)
Survival Alive 146 14 (50.0) 132 (67.7) 0.066
Expired 77 14 (50.0) 63 (32.3)
WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; LNM: lymph node metastasis.
Figure 4: Induction of EMT by LOXL2 through the activation of FAK/Src pathway and upregulation of Snail. 
(A) Expression of EMT-related molecules 24 and 48 h after the transfection of cells with LOXL2 siRNA/overexpressing plasmid. (B) 
CDH1 (E-cadherin), VIM (vimentin), and SNAI1 (Snail) expression in SW480 and SW620 cells 24 h after the transfection with siLOXL2 
and LOXL2-overexpressing plasmid, respectively. GAPDH was used as an internal control. (C) Expression of EMT-related molecules in 
cells transfected with siLOXL2 and LOXL2-overexpressing plasmid.
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Metastatic cells generally have a higher migratory 
potential compared with that of the primary tumor cells. 
SW480 and SW620 cell lines have originated from one 
patient. The former was isolated from a primary colorectal 
cancer and the latter from a lymph node metastasis [25]. 
However, the results obtained here demonstrated that 
SW480 cells show higher motility and migratory potential 
than SW620 in vitro. Previously, different studies reported 
controversial results when analyzing migratory potential 
of these cells [25–35], which may be due to the alterations 
in cell line characteristic during long-term in vitro 
culturing, or it is possible that SW620 cells underwent 
mesenchymal-epithelial transition (MET), in order to 
establish and grow at the distant metastatic sites [36, 37].
In spite of inverted migratory capacity to conceptual 
expectation, it is possible that SW620 possesses higher 
metastatic potential than SW480 in vivo. It was reported 
in several studies that SW620 cells show an increased 
metastatic potential in xenograft experiments compared 
with that of SW480 cells [38, 39]. Due to the complexity 
of metastatic process, other factors, such as proteolytic 
potential and cancer cell stemness are crucial for this 
process as well [6, 40], and some of these factors may 
be responsible for the observed discrepancy between 
the migratory capacity and metastatic potential of two 
analyzed cell lines. Although high migratory potential 
is not sufficient for the development of metastasis, it is 
necessary, and therefore, our results strongly indicate that 
LOXL2 plays crucial role in the development of CRC 
metastasis.
Although previous reports suggested that LOXL2 
expression may be related to CRC differentiation and 
stage [18, 19], the results of our clinical analysis showed 
a correlation between CRC metastasis rate and LOXL2 
expression, which agrees with the results obtained in 
studies investigating LOXL2 roles in other cancer types 
[13–17], and the study examining the LOH locus in CRC 
patients with liver metastasis [20]. Among 13 genes at the 
LOH locus, LOXL2 expression was shown to be increased 
in patients with liver metastasis, compared with that in 
the normal tissues or matched primary cancer by locus 
mutation, which supports our conclusion that LOXL2 
induces EMT/metastasis. Furthermore, LOXL2 expression 
was shown to be associated with patient survival rate, 
suggesting that the levels of this molecule may serve as a 
prognostic marker in CRC.
Currently, different characteristics are used in 
clinic for the classification of CRCs. Microsatellite 
Figure 5: LOXL2 IHC analysis in CRC tissues and the correlation between this parameter and the survival of CRC 
patients. (A) IHC analysis of LOXL2 expression in CRC tissues. Representative images of normal colon tissue, CRC tissue with low 
LOXL2 expression, and CRC tissue with high LOXL2 expression are presented (magnification, 200 ×). (B) Correlation between the overall 
survival rates of CRC patients and LOXL2 expression. High LOXL2 expression was correlated with poor patient survival (log-rank Mantel-
Cox test, p = 0.024). 
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instability (MSI), one of the essential factors used for the 
classification of CRCs, occurs due to the deficiencies in 
mismatch repair (MMR) mechanism, believed to represent 
a main cause of carcinogenesis [41, 42]. Clinically, five to 
eight specific loci in CRC patients are investigated in order 
to establish the diagnosis of MSI- or microsatellite stable 
(MSS)-CRC, and this process is crucial for the selection of 
therapeutic strategies [43]. While it is believed that MSI-
CRCs have a more positive prognosis and lower frequency 
of metastasis [44], 80~85% of CRCs are diagnosed as 
MSS-CRCs [45], requiring further molecular studies of 
the mechanism of carcinogenesis and metastasis process. 
Here, we used MSS-CRC cells, since only six patients 
(2.7%) were diagnosed as MSI-CRC in TMA analysis 
performed in this study (data not shown), but all screened 
cell lines were of MSS-CRC origin.
In conclusion, the results obtained in our study 
demonstrated that LOXL2 expression levels may be 
of clinical significance in CRC, and the mechanisms 
underlying the effects of this molecule include the 
activation of FAK/Src signaling and the stabilization of 
Snail. The analysis of clinicopathological parameters of 
CRC patients demonstrated that LOXL2 may represent a 
valuable prognostic marker for these patients. Furthermore, 
molecular mechanisms underlying LOXL2-mediated EMT 
induction in CRC, which we elucidated here, may lead to 
the development of improved therapeutic strategies for the 
treatment of CRC metastasis. Targeting of transcription 
factors or signaling molecules associated with the process 
of EMT may generally have harmful effects, due to the 
presence and functions of these molecules in the healthy 
tissues. However, LOXL2 is generally not expressed in 
normal colon tissues [46], which may allow a specific 
targeting of CRC metastatic cells, and, since LOXL2 is an 
enzyme, its potential inhibitors can be easily and rapidly 
screened. The clinical application of several inhibitors 
targeting LOXL2 is being investigated currently, although 
not for the treatment of CRC [47, 48]. Taken together, our 
results and previous reports demonstrate that LOXL2 may 




All CRC cell lines (SW480, SW620, HT-29, COLO 
205, and WiDr) were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA), and 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Hyclone, Logan, UT, USA) supplemented with 10% fetal 
bovine serum (FBS; Hyclone) and 10 U/mL of penicillin-
streptomycin (Hyclone). All cell lines were routinely 
tested for mycoplasma contamination and cell lines used 
in subsequent experiments (SW480 and SW620) were 
authenticated by short tandem repeat profiling at the 
Research Institute of National Cancer Center (Republic 
of Korea).
HUVEC cells were purchased from ATCC, and 
cultured in Endothelial Cell Growth medium (EGM-2; 
Lonza, Walkersville, MD, USA) supplemented with 10% 
FBS.
Knockdown and ectopic expression of LOXL2
For LOXL2 knockdown, cells were transfected with 
small interfering (si)RNA targeting LOXL2 (siLOXL2; 
5′-GCCACAUAGGUGGUUCCUUCAUU-3′) or non 
specific oligonucleotide (siControl; 5′-CGUUAAUCG 
CGUAUAAUACGCGUA-3′) using Lipofectamine 
RNAiMAX (Invitrogen/Life Technologies, Green Island, 
NY, USA), according to the manufacturer’s instructions. 
For the ectopic expression of LOXL2, cells 
were transfected with LOXL2-expressing plasmid 
(pcDNA3.1(+)−hLOXL2 [17]) using Lipofectamine 
2000 (Invitrogen/Life Technologies) according to the 
manufacturer’s instructions. 
Reverse transcription-polymerase chain reaction 
(RT-PCR)
Total RNA was extracted from CRC cells using 
TRIZOL reagent (Gibco BRL/Life Technologies, 
Green Island, NY, USA), and cDNA was subsequently 
synthesized using SuperScriptIII First-Strand Synthesis 
System (Invitrogen/Life Technologies), according to the 
manufacturer’s instructions. Synthesized cDNAs were 
used as a template for subsequent PCR, determining the 
levels of SNAI1, LOXL2, VIM, CDH1, and GAPDH. 
Primer sequences used in each PCR set are shown in 
Supplementary Table 1. 
Western blot analysis
Cells were lysed with radioimmunoprecipitation 
assay (RIPA) buffer (Sigma-Aldrich, St. Louis, MO, 
USA) supplemented with protease inhibitors and 
sampled in protein sample buffer (250 mM Tris-Cl, 1.6 
mM EDTA, 8% sodium dodecyl sulfate (SDS), 40% 
glycerol, 0.02% Pyronin Y dye, 1.5% 2′-mercaptoethanol). 
Protein samples were separated using 8–10% SDS-
polyacrylamide gel electrophoresis and transferred 
onto nitrocellulose membranes, which were blocked 
and probed with antibodies against LOXL2 (Origene, 
Rockville, MD, USA), SNAI1 (Cell Signaling, Danvers, 
MA, USA), phosphor-FAK;Tyr576, and FAK (Santa 
Cruz Biotechnology, CA, USA), phosphor-Src;Tyr418 
(Millipore, Billerica, MA, USA), Src (Santa Cruz 
Biotechnology), CDH1 (BD Biosciences, Sparks, MD), 
VIM (Dako, Glostrup, Denmark), and β-actin (Sigma-
Aldrich). The blots were prepared using WesternBright 
Sirius solution (Advansta; Menlo Park, CA, USA) and 
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analyzed with enhanced chemiluminescence using 
ImageQuant LAS Chemi-luminescent Image Analyzer 
(GE Healthcare/Life Technologies, Green Island, NY, 
USA).
Wound-healing assay
In order to induce a wound in a monolayer of CRC 
cells, a culture insert (IBIDI, Martinsried, Germany), 
consisting of two reservoirs separated by a 500-μm thick 
wall, was placed into each well of six-well plates, and 
5 × 104 cells were added into the two reservoirs. After 24 
h of incubation at 37°C, the insert was gently removed, 
and the cells were allowed to migrate for 5 days. Images 
were taken every 24 h using Olympus IX71 inverted 
microscope equipped with a digital camera (Olympus 
France, Rungis, France).
For the comparative analysis of migratory potential 
according to LOXL2 expression in SW480 cells, control 
SW480 cells and LOXL2-silenced SW480 cells (5 × 104 
cells/well) were seeded into 96-well Essen ImageLock 
microplates (Essen BioScience, Ann Arbor, MI, USA), and 
incubated at 37°C for 18 h. Cell monolayers were scratched 
using a 96-well Wound Maker (Essen BioScience), and the 
wells were washed with phosphate-buffered saline (PBS) 
to remove the detached cells. Images of the wounds were 
automatically recorded at every 6 h for 96 h using IncuCyte 
ZOOM software (Essen BioScience).
Transwell migration and trans-endothelial 
migration assays
The migratory capacity of CRC cells was assessed 
in vitro using transwell migration chambers (Corning, NY, 
USA) in accordance with the manufacturer’s instructions. 
Briefly, cells were serum-starved for 24 h, then detached 
by brief trypsinization, and resuspended in the serum-free 
medium. For each well, 2–4 × 105 cells were seeded onto 
0.1% gelatin-coated insert in the transwell chamber (8-μm 
pore size and 6.5-mm diameter), and the inserts were set 
in chambers filled with 400 μL of complete medium. Cells 
were incubated in a CO2 incubator at 37°C for 36 or 72 h, 
and the inserts were fixed with methanol and stained with 
hematoxylin-eosin solution (Sigma-Aldrich). Following 
the staining, the upper surface of membranes, containing 
the remaining non-migrated cells, was wiped with cotton 
swabs, and the lower membrane surfaces, containing cells 
that migrated, were mounted onto slides. Images were 
taken using Olympus IX71 inverted microscope equipped 
with a digital camera (Olympus, France).
For trans-endothelial migration assay, 3 × 104 
HUVECs were seeded onto 0.1% gelatin-coated insert 
24 h prior to the seeding of 2–4 × 105 carboxyfluorescein 
succinimidyl ester-labeled (CFSE; Thermo Fisher, Waltham, 
MA, USA) cells resuspended in serum-free medium. 
The inserts were set in the wells filled with the complete 
medium. After 36 or 72 h of incubation, the upper surface 
of the membranes was wiped with cotton swabs and the 
migrated cells on the lower surface fixed and mounted 
onto slides. Images were taken using Olympus DP71 
fluorescent microscope equipped with a digital camera 
(Olympus France, Rungis, France) with green fluorescent 
protein (GFP) filter, in order to visualize CFSE-labeled 
cells.
All experiments were performed three times and, in 
each experiment, images were taken in 4–5 random fields 
per slide at 100× magnification.
Cell proliferation assay
For the comparison of proliferation rates between 
five investigated CRC cell lines, 5 × 104 cells of each line 
were seeded into 12-well plates and cell numbers were 
manually determined using disposable hemocytometers 
every 24 h.
For the proliferation assay with LOXL2-knockdown/
overexpression cells, Cell Counting Kit-8 (Dojindo 
Molecular Technologies Inc, Rockville, MD, USA) 
was used, according to the manufacturer’s instructions. 
Relative proliferation rates were calculated by detecting 
absorbance at 450 nm using Epoch Microplate 
Spectrophotometer (BioTek Instruments Inc, Winooski, 
VT, USA).
CRC patient selection and tissue microarray 
construction
Patients who underwent surgical resection due to 
CRC in 2003 and 2004 at Severance Hospital (Seoul, 
Republic of Korea) were included in this study. Patients 
treated with neoadjuvant chemoradiation therapy, which 
may affect the EMT process [49], were excluded. Various 
clinicopathologic factors, such as the age at operation, 
gender, size and location of tumor, and clinical follow-up 
data were obtained from the review of medical records. 
Overall survival time was estimated from the date of 
curative resection to the date of the last follow-up or death 
from any cause.
Pathologic factors, such as histologic grade of tumor 
and pathologic TNM staging according to the 7th American 
Joint Committee on Cancer criteria were obtained from 
the slides independently reviewed by two pathologists 
(C. K. Park and H. Kim). Two cores of representative 
tumor area and one core of the representative normal 
area were extracted from each case for tissue microarray 
construction as previously described [13]. This study was 
approved by the Institutional Review Board of Severance 
Hospital, Seoul, Republic of Korea (IRB 4-2012-0026), 
and the study was conducted according to the principles 
expressed in the Declaration of Helsinki. 
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IHC staining and analysis
Four-micrometer large tissue sections from the tissue 
microarray recipient blocks were used for IHC, which was 
performed using the Ventana Discovery XT automated 
staining system (Ventana Medical Systems, Inc., Tucson, 
AZ, USA) and anti-LOXL2 antibody (Origene). 
Immunostained slides were evaluated 
by two pathologists (C. K. Park and H. Kim) 
independently. LOXL2 expression was categorized as 
negative, focal positive, and positive. Further, these 
samples were considered as low expression samples 
if they were negative or focal positive, while positive 
samples were considered high expression samples. 
Statistical analysis
For transmigration assay and trans-endothelial 
migration assay, statistical analyses and the determination of 
p-values were performed by using Student’s t-test, with IBM 
SPSS Statistics software v. 23 (SPSS Inc., Chicago, IL, USA).
For the analysis of clinicopathological characteristics, 
SPSS for Windows version 21.0 (SPSS Inc.) was used. 
Mann-Whitney U-test and Fisher’s exact test were used 
for the analysis of various clinicopathologic factors. 
p-values < 0.05 were considered statistically significant. 
Kaplan-Meier survival curves with log-rank statistics were 
applied to evaluate time to survival.
Abbreviations 
CRC, colorectal cancer; EMT, epithelial-
mesenchymal transition; ECM, extracellular matrix; FAK, 
focal adhesion kinase; GSK3β, glycogen synthase kinase 3 
beta; HUVEC, human umbilical vein endothelial cell; IHC, 
immunohistochemistry; LOH, loss of the heterozygosity; 
LOX, lysyl oxidase; LOXL2, lysyl oxidase-like 2.
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